Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

 Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

Shots:

  • Novartis gets an exclusive WW right to develop and commercialize therapeutic applications for FAP assets including FAPI-46 and FAPI-74 under its collaboration with iTheranostics, which is an affiliate of SOFIE Biosciences
  • The agreement also consists of co-exclusive rights for Novartis to develop imaging applications for FAP assets
  • The company will continue to reimagine cancer care through the development of a robust radioligand therapy portfolio and actively investigate across multiple tumor types

Click here to­ read full press release/ article | Ref: Novartis | Image: Dallas Morning News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post